GlassScriptPhysician profile
David Neblett
NPI 1720466741
$414.32
in general payments reported to CMS, 2019-2025
11 companies · $44.83 in 2025
The $44.83 reported for 2025 was less than what a typical Sports Medicine (Pediatrics) provider received nationally (typical 2025 total: $59.86).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.52 · 2020: $15.63 · 2021: $68.82 · 2022: $91.95 · 2023: $14.27 · 2024: $93.30 · 2025: $44.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $93.30 | 2024 | Airsupra |
| Djo, LLC | $85.52 | 2019 | |
| Quidel Corporation | $54.63 | 2022 | |
| Amgen INC. | $30.93 | 2020-2025 | Krystexxa |
| Vertex Pharmaceuticals Incorporated | $29.53 | 2025 | |
| Pacira Therapeutics, INC. | $27.25 | 2021 | |
| Radius Health, INC. | $25.47 | 2021 | |
| Seqirus USA INC | $18.82 | 2022 | |
| Abbvie INC. | $18.50 | 2022 | |
| Depuy Synthes Sales INC. | $16.10 | 2021 | |
| Fidia Pharma USA INC. | $14.27 | 2023 | Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Neblett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.